Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

[Regression of peripheral and pulmonary rheumatoid nodules under therapy with rituximab].

Braun MG, Wagener P.

Z Rheumatol. 2013 Mar;72(2):166-71. doi: 10.1007/s00393-012-1054-0. German.

PMID:
23052405
2.

Efficacy of rituximab in the treatment of pulmonary rheumatoid nodules: findings in 10 patients from the French AutoImmunity and Rituximab/Rheumatoid Arthritis registry (AIR/PR registry).

Glace B, Gottenberg JE, Mariette X, Philippe R, Pereira B, Lequerré T, Berthelot JM, Dougados M, Toussirot E, Pham T, Allanore Y, Loeuille D, Euller-Ziegler L, Soubrier M.

Ann Rheum Dis. 2012 Aug;71(8):1429-31. doi: 10.1136/annrheumdis-2011-200915. Epub 2012 Apr 13. No abstract available.

PMID:
22504557
3.

Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.

Narváez J, Díaz-Torné C, Ruiz JM, Hernández MV, Torrente-Segarra V, Ros S, Rodriguez de la Serna A, Díaz-López C, Sanmartí R, Nolla JM.

Semin Arthritis Rheum. 2011 Dec;41(3):401-5. doi: 10.1016/j.semarthrit.2011.06.005. Epub 2011 Aug 20.

PMID:
21862107
4.

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.

Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Gabay C, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF.

Ann Rheum Dis. 2011 Sep;70(9):1575-80. doi: 10.1136/ard.2010.148759. Epub 2011 May 12.

PMID:
21571731
5.

Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital.

Couderc M, Mathieu S, Pereira B, Glace B, Soubrier M.

Arthritis Care Res (Hoboken). 2013 Apr;65(4):648-52. doi: 10.1002/acr.21865.

6.

Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs.

Narvaez J, Díaz-Torné C, Ruiz JM, Hernandez MV, Torrente-Segarra V, Ros S, Rodriguez de la Serna A, Díaz-López C, Sanmartí R, Nolla JM.

Clin Exp Rheumatol. 2011 Nov-Dec;29(6):991-7. Epub 2011 Dec 22.

PMID:
22133052
7.

Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial.

Haraoui B, Bokarewa M, Kallmeyer I, Bykerk VP; RESET Investigators.

J Rheumatol. 2011 Dec;38(12):2548-56. doi: 10.3899/jrheum.110444. Epub 2011 Oct 1.

8.

Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register.

Sebastiani M, Anelli MG, Atzeni F, Bazzani C, Farina I, Fedele AL, Favalli EG, Fineschi I, Cino N, Dal Forno I, Gasparini S, Cassarà E, Giardina R, Bruschi E, Addimanda O, Cassone G, Lopriore S, Sarzi-Puttini P, Filippini M, Pignatti F, Gremese E, Biggioggero M, Manganelli S, Amato G, Caimmi C, Salaffi F, Iannone F, Ferri C, Sandri G, Lapadula G, Gorla R, Govoni M, Ferraccioli G, Marchesoni A, Galeazzi M, Foti R, Carletto A, Cantini F, Triolo G, Epis OM, Salvarani C; Italian Study Group on Early Arthritides (GISEA).

Joint Bone Spine. 2014 Dec;81(6):508-12. doi: 10.1016/j.jbspin.2014.06.011. Epub 2014 Jul 28.

PMID:
25082646
9.

Efficacy of rituximab on pulmonary nodulosis occurring or increasing in patients with rheumatoid arthritis during anti-TNF-α therapy.

De Stefano R, Frati E, Nargi F, Menza L.

Clin Exp Rheumatol. 2011 Jul-Aug;29(4):752-3. Epub 2011 Sep 1. No abstract available.

PMID:
21906436
10.

High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis.

Gardette A, Ottaviani S, Tubach F, Roy C, Nicaise-Roland P, Palazzo E, Gill G, Meyer O, Dieudé P.

Joint Bone Spine. 2014 Oct;81(5):416-20. doi: 10.1016/j.jbspin.2014.06.001. Epub 2014 Jul 3.

PMID:
24998790
11.

Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study.

Rigby WF, Mease PJ, Olech E, Ashby M, Tole S.

J Rheumatol. 2013 May;40(5):599-604. doi: 10.3899/jrheum.120924. Epub 2013 Apr 1.

12.

Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.

Quartuccio L, Fabris M, Salvin S, Atzeni F, Saracco M, Benucci M, Cimmino M, Morassi P, Masolini P, Pellerito R, Cutolo M, Puttini PS, De Vita S.

Rheumatology (Oxford). 2009 Dec;48(12):1557-9. doi: 10.1093/rheumatology/kep314. Epub 2009 Sep 29.

13.

Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry.

De Keyser F, Hoffman I, Durez P, Kaiser MJ, Westhovens R; MIRA Study Group.

J Rheumatol. 2014 Sep;41(9):1761-5. doi: 10.3899/jrheum.131279. Epub 2014 Aug 15.

PMID:
25128506
14.

[Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNFalpha agents failed are associated with response to rituximab in rheumatoid arthritis].

Quartuccio L, Salvin S, Saracco M, Lombardi S, Fabris M, Mansutti E, Maset M, Pellerito S, De Vita S.

Reumatismo. 2009 Jul-Sep;61(3):182-6. Italian.

15.

Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis.

Conti F, Ceccarelli F, Perricone C, Alessandri C, Conti V, Massaro L, Truglia S, Spinelli FR, Spadaro A, Valesini G.

Rheumatology (Oxford). 2011 Jun;50(6):1148-52. doi: 10.1093/rheumatology/keq436. Epub 2011 Jan 28.

16.

Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure.

Solau-Gervais E, Prudhomme C, Philippe P, Duhamel A, Dupont-Créteur C, Legrand JL, Houvenagel E, Flipo RM.

Joint Bone Spine. 2012 May;79(3):281-4. doi: 10.1016/j.jbspin.2011.05.002. Epub 2011 Jul 2.

PMID:
21724444
17.

[Development and/or increase of rheumatoid nodules in RA patients following leflunomide therapy].

Braun MG, Van Rhee R, Becker-Capeller D.

Z Rheumatol. 2004 Feb;63(1):84-7. German.

PMID:
14991281
18.

Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register.

Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM; British Society for Rheumatology Biologics Register.

Arthritis Care Res (Hoboken). 2012 Aug;64(8):1108-15. doi: 10.1002/acr.21663.

19.

Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.

Lal P, Su Z, Holweg CT, Silverman GJ, Schwartzman S, Kelman A, Read S, Spaniolo G, Monroe JG, Behrens TW, Townsend MJ.

Arthritis Rheum. 2011 Dec;63(12):3681-91. doi: 10.1002/art.30596.

20.

Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis.

Sellam J, Rouanet S, Hendel-Chavez H, Abbed K, Sibilia J, Tebib J, Le Loët X, Combe B, Dougados M, Mariette X, Taoufik Y.

Arthritis Rheum. 2011 Dec;63(12):3692-701. doi: 10.1002/art.30599.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk